Home / News Briefs  / NuMe Offers Safe, Effective Treatment for OCD and Depression

NuMe Offers Safe, Effective Treatment for OCD and Depression

In a groundbreaking move in 2018, the United States Food and Drug Administration (FDA) approved transcranial magnetic stimulation (TMS) as a treatment for obsessive-compulsive personality disorder (OCD). According to David Kent, M.D., founder of NuMe TMS

In a groundbreaking move in 2018, the United States Food and Drug Administration (FDA) approved transcranial magnetic stimulation (TMS) as a treatment for obsessive-compulsive personality disorder (OCD).

According to David Kent, M.D., founder of NuMe TMS Clinics, TMS is an innovative therapy that uses magnetic fields to stimulate the brain’s nerve cells. This noninvasive procedure has historically been used to improve symptoms of depression, even when more traditional depression treatments like antidepressant drugs have failed.

During a Brainsway Deep TMS Therapy session, a cushioned helmet containing an electromagnetic coil is placed on the patient’s head, sending a magnetic pulse that stimulates the region of the brain involved in mood regulation. This treatment involves daily, weekday, 20-minute treatments for six to eight weeks. Kent reports that most patients see dramatic improvement after four weeks of treatments. Unlike other antidepressant alternatives, TMS therapy does not require hospitalization or anesthesia, and entails no memory loss.

Kent has been using Brainsway Deep TMS to treat depression since early 2017. “Brainsway has the only FDA-approved device on the market, making us the first in Idaho to offer this device for OCD treatment,” says this full-time, private practice adult psychiatrist who is currently affiliated with St. Alphonsus Regional Medical Center and St. Luke’s Regional Medical Center.

 

Location: Within Sage Health Care, 413 N. Allumbaugh St., Ste. 102, Boise. For more information, call 208-863-0860, email DrKent@NuMeTms.com or visit NuMeTms.com. June 2019

info@websmithguy.com

Review overview
NO COMMENTS

Sorry, the comment form is closed at this time.